Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Moon

Showing results (131-140 of 136) with videos related to

Pageof 14
Sort By:
You have reached the last page of results.This site can display upto 136 results.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Cancer Discovery|April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Science (New York, N.Y.)|June 14, 2022
Immune boosting by B.1.1.529 <b>(</b>Omicron) depends on previous SARS-CoV-2 exposureCatherine J Reynolds, Corinna Pade, Joseph M Gibbons, et al.
Pageof 14

Showing results (131-140 of 136) with videos related to

Sort By:
Pageof 14
You have reached the last page of results.This site can display upto 136 results.
Nature Medicine|August 26, 2025
Publisher Correction: Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Cancer|January 29, 2026
Neoadjuvant PD-1 blockade in surgically resectable desmoplastic melanoma: cohort A of the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Nature Medicine|August 14, 2025
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trialKari L Kendra, Shay L Bellasea, Zeynep Eroglu, et al.
Cancer Discovery|April 21, 2026
Cellular neighborhoods govern antitumor T-cell infiltration following anti-CTLA-4 in melanoma with primary resistance to anti-PD-1Katie M Campbell, Daniel G Chen, Zaid E Bustami, et al.
The New England Journal of Medicine|March 1, 2023
Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced MelanomaSapna P Patel, Megan Othus, Yuanbin Chen, et al.
Science (New York, N.Y.)|June 14, 2022
Immune boosting by B.1.1.529 <b>(</b>Omicron) depends on previous SARS-CoV-2 exposureCatherine J Reynolds, Corinna Pade, Joseph M Gibbons, et al.
Pageof 14